| UTHEALTH HOME ABOUT SBMI A-Z WEBMAIL INSIDE THE UNIVERSITY |
|
|||||||
|
Kinase Fusion Gene:RALA_CDK13 |
Kinase Fusion Protein Summary |
 Kinase Fusion gene summary |
| Kinase Fusion partner gene information | Kinase Fusion gene name: RALA_CDK13 | KinaseFusionDB ID: KFG5270 | FusionGDB2.0 ID: KFG5270 | Hgene | Tgene | Gene symbol | RALA | CDK13 | Gene ID | 5898 | 8621 | |
| Gene name | RAS like proto-oncogene A | cyclin dependent kinase 13 | ||||||||||
| Synonyms | HINCONS|RAL | CDC2L|CDC2L5|CHDFIDD|CHED|hCDK13 | ||||||||||
| Cytomap | 7p14.1 | 7p14.1 | ||||||||||
| Type of gene | protein-coding | protein-coding | ||||||||||
| Description | ras-related protein Ral-ARALA Ras like proto-oncogene ARAS-like protein ARas family small GTP binding protein RALAras related GTP binding protein Av-ral simian leukemia viral oncogene homolog A (ras related) | cyclin-dependent kinase 13CDC2-related protein kinase 5cell division cycle 2-like protein kinase 5cell division protein kinase 13cholinesterase-related cell division controller | ||||||||||
| Modification date | 20240305 | 20240407 | ||||||||||
| UniProtAcc | P11233 | Q14004 | ||||||||||
| Ensembl transtripts involved in fusion gene | ENST ids | ENST00000468201, ENST00000005257, | ENST00000181839, ENST00000340829, ENST00000484589, | |||||||||
| Context (manual curation of fusion genes in KinaseFusionDB) | PubMed: RALA [Title/Abstract] AND CDK13 [Title/Abstract] AND fusion [Title/Abstract] | |||||||||||
| Most frequent breakpoint (based on all fusion genes of FusionGDB 2.0) | RALA(39663424)-CDK13(40027197), # samples:1 CDK13(40041630)-RALA(39745722), # samples:2 | |||||||||||
| Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez |
| Partner | Gene | GO ID | GO term | PubMed ID |
| Hgene | RALA | GO:0017157 | regulation of exocytosis | 20005108 |
| Hgene | RALA | GO:0032956 | regulation of actin cytoskeleton organization | 10051605 |
| Hgene | RALA | GO:0051491 | positive regulation of filopodium assembly | 10051605 |
| Hgene | RALA | GO:0051665 | membrane raft localization | 20005108 |
| Tgene | CDK13 | GO:0009966 | regulation of signal transduction | 26748711 |
| Tgene | CDK13 | GO:0032968 | positive regulation of transcription elongation by RNA polymerase II | 26748711 |
| Tgene | CDK13 | GO:0045944 | positive regulation of transcription by RNA polymerase II | 20952539 |
| Kinase Fusion gene breakpoints across RALA (5'-gene) * Click on the image to open the UCSC genome browser with custom track showing this image in a new window. |
| Kinase Fusion gene breakpoints across CDK13 (3'-gene) * Click on the image to open the UCSC genome browser with custom track showing this image in a new window. |
Top |
Kinase Fusion Gene Sample Information |
| Kinase Fusion gene information. |
| Kinase Fusion gene information from four resources (ChiTars 5.0, ChimerDB 4.0, COSMIC, and CCLE) * All genome coordinats were lifted-over on hg19. * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
| Source | Sample | Hgene | Hchr | Hbp | Tgene | Tchr | Tbp |
| ChimerDB4 | TCGA-HU-A4GJ | RALA | chr7 | 39663424 | CDK13 | chr7 | 40027197 |
| CCLE | EFO-21 | RALA | chr7 | 39663424 | CDK13 | chr7 | 40037093 |
Top |
Kinase Fusion ORF Analysis |
| Kinase Fusion information from ORFfinder translation from full-length transcript sequence from KinaseFusionDB. |
| Henst | Tenst | Hgene | Hchr | Hbp | Tgene | Tchr | Tbp | Seq length (transcript) | Seq length (amino acids) |
Top |
Kinase Fusion Amino Acid Sequences |
| For individual full-length fusion transcript sequence from KinaseFusionDB, we ran ORFfinder and chose the longest ORF among the all predicted ones. |
| >Henst_Tenst_Hgene_Hchr_Hbp_Tgene_Tchr_Tbp_length(fusion AA)_AAseq |
Multiple Sequence Alignment of All Fusion Protein Isoforms |
Top |
Kinase Fusion Protein Functional Features |
| Four levels of functional features of fusion genes Go to FGviewer search page for the most frequent breakpoint (https://ccsmweb.uth.edu/FGviewer/:39663424/:40027197) - FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels. - How to search 1. Put your fusion gene symbol. 2. Press the tab key until there will be shown the breakpoint information filled. 4. Go down and press 'Search' tab twice. 4. Go down to have the hyperlink of the search result. 5. Click the hyperlink. 6. See the FGviewer result for your fusion gene. |
 |
| Main function of each fusion partner protein. (from UniProt) |
| Hgene | Tgene |
| RALA | CDK13 |
| FUNCTION: Multifunctional GTPase involved in a variety of cellular processes including gene expression, cell migration, cell proliferation, oncogenic transformation and membrane trafficking. Accomplishes its multiple functions by interacting with distinct downstream effectors (PubMed:18756269, PubMed:19306925, PubMed:20005108, PubMed:21822277, PubMed:30500825). Acts as a GTP sensor for GTP-dependent exocytosis of dense core vesicles. The RALA-exocyst complex regulates integrin-dependent membrane raft exocytosis and growth signaling (PubMed:20005108). Key regulator of LPAR1 signaling and competes with GRK2 for binding to LPAR1 thus affecting the signaling properties of the receptor. Required for anchorage-independent proliferation of transformed cells (PubMed:19306925). During mitosis, supports the stabilization and elongation of the intracellular bridge between dividing cells. Cooperates with EXOC2 to recruit other components of the exocyst to the early midbody (PubMed:18756269). During mitosis, also controls mitochondrial fission by recruiting to the mitochondrion RALBP1, which mediates the phosphorylation and activation of DNM1L by the mitotic kinase cyclin B-CDK1 (PubMed:21822277). {ECO:0000269|PubMed:18756269, ECO:0000269|PubMed:19306925, ECO:0000269|PubMed:20005108, ECO:0000269|PubMed:21822277, ECO:0000269|PubMed:30500825}. | FUNCTION: Cyclin-dependent kinase which displays CTD kinase activity and is required for RNA splicing. Has CTD kinase activity by hyperphosphorylating the C-terminal heptapeptide repeat domain (CTD) of the largest RNA polymerase II subunit RPB1, thereby acting as a key regulator of transcription elongation. Required for RNA splicing, probably by phosphorylating SRSF1/SF2. Required during hematopoiesis. In case of infection by HIV-1 virus, interacts with HIV-1 Tat protein acetylated at 'Lys-50' and 'Lys-51', thereby increasing HIV-1 mRNA splicing and promoting the production of the doubly spliced HIV-1 protein Nef. {ECO:0000269|PubMed:16721827, ECO:0000269|PubMed:1731328, ECO:0000269|PubMed:18480452, ECO:0000269|PubMed:20952539}. |
| Retention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, because of limited space for viewing, we only show the protein feature retention information belong to the 13 regional features. All retention annotation result can be downloaded at * Minus value of BPloci means that the break pointn is located before the CDS. |
| - Retained domain in the 5'-partner of fusion protein (protein functional feature from UniProt). |
| Partner | Hgeneene | Hbp | Tgeneene | Tbp | ENST | BPexon | TotalExon | Protein feature loci | BPloci | TotalLen | Feature | Note |
| - Retained domain in the 3'-partner of fusion protein (protein functional feature from UniProt). |
| Partner | Hgeneene | Hbp | Tgeneene | Tbp | ENST | BPexon | TotalExon | Protein feature loci | BPloci | TotalLen | Feature | Note |
Top |
Kinase-Substrate Information of RALA_CDK13 |
| Phosphorylation target of the kinase (phosphosite, 03-17-2024) |
| Kinase | Kinase UniProt Acc | Kinase species | Substrate | Substrate UniProt Acc | Substrate phosphorylated residues | Substrate phosphorylated sites (+/-7AA) | Domain |
| CDK13 | Q14004 | human | SERINC5 | Q86VE9 | S360 | ARCCFCFsPGGEDTE | Serinc |
| CDK13 | Q14004 | human | EIF4EBP1 | Q13541 | S65 | FLMECrNsPVtktPP | eIF_4EBP |
| CDK13 | Q14004 | human | EIF4B | P23588 | S406 | RPRERHPsWRsEEtQ | |
| CDK13 | Q14004 | human | POLR2A | P24928 | S1616 | TPQSPSysPtsPsYS | RNA_pol_Rpb1_R |
| CDK13 | Q14004 | human | EIF4EBP1 | Q13541 | T70 | rNsPVtktPPRDLPt | eIF_4EBP |
| CDK13 | Q14004 | human | POLR2A | P24928 | S1619 | SPSysPtsPsYSPTS | RNA_pol_Rpb1_R |
| CDK13 | Q14004 | human | EIF4EBP1 | Q13541 | T46 | GGtLFsttPGGtRII | eIF_4EBP |
| CDK13 | Q14004 | human | EIF4B | P23588 | S422 | RERsRtGsEssQtGt |
| Biological Network Integration of This Kinase and Substrates (GeneMANIA website) |
| Enriched GO biological processes of the phosphorylation target genes of the kinase |
| Kinase | GOID | GO term | P.adjust |
| CDK13 | ID | Description | 0.00e+00 |
| CDK13 | GO:0006446 | regulation of translational initiation | 5.02e-03 |
| CDK13 | GO:0006413 | translational initiation | 5.52e-03 |
| CDK13 | GO:0032329 | serine transport | 3.03e-02 |
| CDK13 | GO:0006563 | L-serine metabolic process | 3.03e-02 |
| CDK13 | GO:0009070 | serine family amino acid biosynthetic process | 3.06e-02 |
| CDK13 | GO:0045947 | negative regulation of translational initiation | 3.06e-02 |
| CDK13 | GO:0006658 | phosphatidylserine metabolic process | 3.06e-02 |
| CDK13 | GO:0006353 | DNA-templated transcription termination | 3.49e-02 |
| CDK13 | GO:0009069 | serine family amino acid metabolic process | 4.13e-02 |
| CDK13 | GO:0033120 | positive regulation of RNA splicing | 4.28e-02 |
| CDK13 | GO:0015804 | neutral amino acid transport | 4.90e-02 |
| CDK13 | GO:1901607 | alpha-amino acid biosynthetic process | 5.33e-02 |
| CDK13 | GO:0008652 | amino acid biosynthetic process | 5.49e-02 |
| CDK13 | GO:0015807 | L-amino acid transport | 5.95e-02 |
| CDK13 | GO:0006575 | cellular modified amino acid metabolic process | 6.91e-02 |
| CDK13 | GO:0045931 | positive regulation of mitotic cell cycle | 6.91e-02 |
| CDK13 | GO:0042552 | myelination | 6.91e-02 |
| CDK13 | GO:0007272 | ensheathment of neurons | 6.91e-02 |
| CDK13 | GO:0008366 | axon ensheathment | 6.91e-02 |
| CDK13 | GO:0006865 | amino acid transport | 6.91e-02 |
| CDK13 | GO:0031929 | TOR signaling | 7.32e-02 |
| CDK13 | GO:0043484 | regulation of RNA splicing | 7.56e-02 |
| CDK13 | GO:1901605 | alpha-amino acid metabolic process | 8.26e-02 |
| CDK13 | GO:0000082 | G1/S transition of mitotic cell cycle | 8.63e-02 |
| CDK13 | GO:0008654 | phospholipid biosynthetic process | 8.63e-02 |
| CDK13 | GO:0044843 | cell cycle G1/S phase transition | 8.63e-02 |
| CDK13 | GO:0006520 | amino acid metabolic process | 8.63e-02 |
| CDK13 | GO:0006650 | glycerophospholipid metabolic process | 8.63e-02 |
| CDK13 | GO:0017148 | negative regulation of translation | 8.63e-02 |
| CDK13 | GO:0045787 | positive regulation of cell cycle | 8.63e-02 |
| CDK13 | GO:0046394 | carboxylic acid biosynthetic process | 8.63e-02 |
| CDK13 | GO:0051607 | defense response to virus | 8.63e-02 |
| CDK13 | GO:0140546 | defense response to symbiont | 8.63e-02 |
| CDK13 | GO:0016053 | organic acid biosynthetic process | 8.63e-02 |
| CDK13 | GO:0034249 | negative regulation of amide metabolic process | 8.63e-02 |
| CDK13 | GO:0046942 | carboxylic acid transport | 8.63e-02 |
| CDK13 | GO:0015849 | organic acid transport | 8.63e-02 |
| CDK13 | GO:0006644 | phospholipid metabolic process | 8.93e-02 |
| CDK13 | GO:0046486 | glycerolipid metabolic process | 9.04e-02 |
| CDK13 | GO:0051347 | positive regulation of transferase activity | 9.34e-02 |
| CDK13 | GO:0009615 | response to virus | 9.50e-02 |
| CDK13 | GO:0015711 | organic anion transport | 9.50e-02 |
| CDK13 | GO:0044772 | mitotic cell cycle phase transition | 9.75e-02 |
| CDK13 | GO:0008380 | RNA splicing | 9.75e-02 |
Top |
Related Drugs to RALA_CDK13 |
| Drugs used for this fusion-positive patient. (Manual curation of PubMed, 04-30-2022 + MyCancerGenome) |
| Hgene | Tgene | Drug | Source | PMID |
| Distribution of the number of studies mentioning RALA-CDK13 and kinase inhibitors the PubMed Abstract (04-01-2024) |
| Fusion gene - drug pair 1 | Fusion gene - drug pair 2 | PMID | Publication date | DOI | Study title |
Top |
Related Diseases to RALA_CDK13 |
| Diseases that have this fusion gene. (Manual curation of PubMed, 04-30-2022 + MyCancerGenome) |
| Hgene | Tgene | Disease | Source | PMID |
| Related diseases from the literature mentioned this fusion gene and drug. (PubMed, 04-01-2024) |
| MeSH ID | MeSH term |
| Diseases associated with fusion partners. (DisGeNet 4.0) |
| Partner | Gene | Disease ID | Disease name | # pubmeds | Source |
Top |
Clinical Trials of the Found Drugs/Small Molecules |
| Statistics of the Clinical Trials of the Found Kinase Inibitors from clinicaltrials.gov (06-17-2024) |
| Clinical Trials from clinicaltrials.gov (06-17-2024) |
| Fusion Gene | Kinase Inhibitor | NCT ID | Study Status | Phases | Disease | # Enrolment | Date |
Copyright 2024-Present -The University of Texas Health Science Center at Houston
Web File Viewing | Emergency Information |Campus Carry|Site Policies |